The Covid-19 pill from Pfizer Inc. failed to prevent symptomatic infections in adults who had been exposed to the pandemic virus, a late-stage study found.

Pfizer said Friday that the drug, named Paxlovid, failed the study’s main objective of meaningfully reducing the risk of confirmed and symptomatic Covid-19 infections in adults who were exposed to the virus by someone in their household.

To Read the Full Story

This post first appeared on wsj.com

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Two Royal Caribbean cruise passengers test positive for Covid

Two passengers on a Royal Caribbean cruise ship tested positive for Covid-19,…

‘SNL’ roasts embattled Rep. Matt Gaetz

“Saturday Night Live” roasted U.S. Rep. Matt Gaetz following Tuesday’s New York…

Eminem takes a knee during Super Bowl halftime performance 

In the moments after performing his hit song “Lose Yourself” to a…

Clorox Books Record Sales Jump

Clorox Co.’s sales jumped 27%, the fastest growth in at least two…